Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 11/20 | 0.57 |
| ▸ | MET | P08581 | 6/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378058 | 0.76 | RPS6KA5 (0.59) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL256322 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL27987760 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL10197264 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL3222371 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL12011230 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL1446137 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL29509090 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL31609660 | 0.74 | RPS6KA5 (0.52) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL30241905 | 0.72 | SLC22A12 (0.56) | RPS6KA5METRPS6KA4CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0916669-B1 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | LILLY CO ELI (US) | 2003-04-09 | — | — | EP | claimed |
| CN-1278814-A | Pyrrolo [3,2-b] pyridine processes and intermediates | LILLY CO ELI (US) | 2001-01-03 | — | — | CN | claimed |
| US-6150525-A | Pyrrolo [3,2-b]pyridine processes and intermediates | ELI LILLY AND COMPANY (US) | 2000-11-21 | — | — | US | claimed |
| EP-0916669-A2 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | claimed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-03-26 | — | — | US | disclosed |
| US-20140135342-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| EP-1513832-B1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | disclosed |
| CN-1278814-A | Pyrrolo [3,2-b] pyridine processes and intermediates | LILLY CO ELI (US) | 2001-01-03 | — | — | CN | disclosed |
| US-6150525-A | Pyrrolo [3,2-b]pyridine processes and intermediates | ELI LILLY AND COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| EP-0916669-A2 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | RPS6KA5 1542/4885MET 4057/4885RPS6KA4 2282/4885 |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | RPS6KA5 344/4885MET 4522/4885RPS6KA4 934/4885 |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | RPS6KA5 1951/4885MET 4486/4885RPS6KA4 3033/4885 |
| US-20140135342-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | RPS6KA5 1951/4885MET 4486/4885RPS6KA4 3033/4885 |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | RPS6KA5 1542/4885MET 4057/4885RPS6KA4 2282/4885 |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | RPS6KA5 344/4885MET 4522/4885RPS6KA4 934/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | RPS6KA5 1165/4885MET 4367/4885RPS6KA4 1959/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | RPS6KA5 174/4885MET 2398/4885RPS6KA4 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.